Patents Assigned to Ascenta Therapeutics, Inc.
  • SPIRO-OXINDOLE MDM2 ANTAGONISTS
    Publication number: 20120122947
    Abstract: Provided herein are compounds, compositions, and methods in the field of medicinal chemistry. The compounds and compositions provided herein relate to spiro-oxindoles which function as antagonists of the interaction between p53 and MDM2, and their use as therapeutics for the treatment of cancer and other diseases.
    Type: Application
    Filed: November 11, 2011
    Publication date: May 17, 2012
    Applicants: THE REGENTS OF THE UNIVERSITY OF MICHIGAN, SANOFI, ASCENTA THERAPEUTICS, INC.
    Inventors: Shaomeng Wang, Yujun Zhao, Wei Sun, Sanjeev Kumar, Lance Leopold, Laurent Debussche, Cedric Barriere, Jean-Christophe Carry, Kwame Amaning
  • Pulsatile Dosing of Gossypol for Treatment of Disease
    Publication number: 20100189683
    Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: December 10, 2009
    Publication date: July 29, 2010
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Process for preparing R-gossypol L-phenylalaninol dienamine
    Patent number: 7696372
    Abstract: This invention relates to a process for preparing R-gossypol L-phenylalaninol dienamine using non-chromatographic purification methods. In particular, the invention is directed to resolution of R- and S-gossypol L-phenylalaninol dienamine by crystallization. R-gossypol L-phenylalaninol dienamine is a useful intermediate for the preparation of R-(?)-gossypol and R-(?)-gossypol acetic acid co-crystal. R-(?)-Gossypol acetic acid and its co-crystal is useful for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: April 13, 2010
    Assignee: Ascenta Therapeutics, Inc.
    Inventors: Ming Guo, Shuguang Zhu, Laure Navarre, Régis Périon
  • Pulsatile Dosing of Gossypol for Treatment of Disease
    Publication number: 20090175869
    Abstract: This invention relates to pulsatile dose administration of gossypol, a gossypol-related compound or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol or gossypol-related compound, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: December 10, 2008
    Publication date: July 9, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang
  • Process for preparing R-gossypol L-Phenylalaninol dienamine
    Publication number: 20090088590
    Abstract: This invention relates to a process for preparing R-gossypol L-phenylalaninol dienamine using non-chromatographic purification methods. In particular, the invention is directed to resolution of R- and S-gossypol L-phenylalaninol dienamine by crystallization. R-gossypol L-phenylalaninol dienamine is a useful intermediate for the preparation of R-(?)-gossypol and R-(?)-gossypol acetic acid co-crystal. R-(?)-Gossypol acetic acid and its co-crystal is useful for inducing apoptosis in cells and for sensitizing cells to the induction of apoptotic cell death.
    Type: Application
    Filed: October 1, 2008
    Publication date: April 2, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Ming Guo, Shuguang Zhu, Laure Navarre, Regis Perion
  • Pulsatile dosing of gossypol for treatment of disease
    Publication number: 20090010878
    Abstract: This invention relates to pulsatile dose administration of gossypol or pharmaceutical compositions thereof for treating diseases, disorders and conditions responsive to gossypol, inhibiting the activity of anti-apoptotic Bcl-2 family proteins, inducing apoptosis in cells and increasing the sensitivity of cells to inducers of apoptosis.
    Type: Application
    Filed: June 2, 2008
    Publication date: January 8, 2009
    Applicant: Ascenta Therapeutics, Inc.
    Inventors: Jon T. Holmlund, Mel Sorensen, Lance Leopold, Dajun Yang